The global avenanthramides market is witnessing strong momentum as industries increasingly prioritize naturally derived bioactive compounds with clinically supported health benefits. The global avenanthramides market size was estimated at USD 145.1 million in 2025 and is projected to reach USD 295.0 million, growing at a CAGR of 9.5% from 2026 to 2033. Rising awareness regarding inflammation-related health conditions, combined with growing consumer preference for clean-label and plant-based ingredients, is significantly accelerating the adoption of avenanthramides across pharmaceuticals, cosmetics, and nutraceutical applications. These oat-derived polyphenols are gaining popularity due to their antioxidant, anti-inflammatory, and skin-soothing properties, making them highly valuable in advanced skincare formulations, dietary supplements, and therapeutic products. Increasing scientific validation and expanding clinical evidence are further strengthening confidence among manufacturers and healthcare providers, contributing to wider commercial utilization across multiple industries.

Growing investments in biotechnology innovation and advanced extraction technologies are also playing a major role in shaping the avenanthramides market landscape. Patents and clinical advancements support this growth, while rising consumer preference for oat-derived actives further boosts adoption. Limited availability of raw materials and complex extraction processes keep prices and margins high, which, in turn, drive greater investment in specialized processing capacity. Manufacturers are focusing on improving purity levels, enhancing scalability, and developing sustainable production methods to meet rising demand while maintaining product efficacy. As consumers continue shifting toward evidence-based natural ingredients, avenanthramides are becoming increasingly important in premium pharmaceutical formulations, high-performance skincare products, and functional wellness solutions worldwide.

Download a free sample copy of the Avenanthramides market report to understand detailed coverage and inclusions in the final report

Key Market Trends & Insights

·         Asia Pacific dominated the market in 2025, accounting for 43.2% of the total revenue share. The region’s dominance is supported by expanding pharmaceutical manufacturing capabilities, rising consumer awareness of natural health ingredients, and strong growth in skincare and nutraceutical sectors. Countries across Asia Pacific are witnessing increased demand for botanical and oat-derived active compounds, encouraging companies to strengthen regional production and research initiatives.

·         By product, the synthetic segment dominated the market and accounted for the largest revenue share of 93.2% in 2025. Synthetic avenanthramides continue to gain traction due to their scalability, consistency, and suitability for industrial applications requiring stable and standardized formulations. Manufacturers are increasingly relying on synthetic production methods to support large-scale commercial demand while maintaining quality control and regulatory compliance.

·         By end use, the pharmaceuticals segment is expected to grow fastest with a CAGR of 9.9% from 2026 to 2033. The increasing focus on anti-inflammatory therapeutics, chronic disease management, and clinically validated plant-derived compounds is supporting rapid adoption within the pharmaceutical industry. Research institutions and biotechnology companies are actively exploring avenanthramides for their therapeutic potential in inflammation-related disorders and advanced treatment formulations.

Looking for more specific insights? Customize this report to suite your business needs

Key Companies & Market Share Insights

The avenanthramides market is led by a few specialized players focused on innovation, clinical validation, and scalable production of oat-derived bioactive compounds for diverse applications. Companies are investing heavily in biotechnology integration, sustainable extraction methods, and strategic collaborations to strengthen their competitive positioning in this evolving market.

·         Among the leading companies, Ceapro Inc. is recognized for its expertise in developing and commercializing oat-derived active ingredients, including avenanthramides. The company focuses on proprietary extraction technologies, clinical validation, and sustainable manufacturing to deliver high-purity bioactives for personal care, nutraceutical, and pharmaceutical applications. Its research-driven approach supports growing demand for scientifically validated natural ingredients across global industries.

·         Another important participant, Cosciens Biopharma Inc., is advancing plant-based bioactive compounds for therapeutic use through extensive clinical research and biotechnology innovation. The company emphasizes safety, efficacy, and anti-inflammatory applications while leveraging strategic partnerships to develop innovative treatments targeting inflammation and related health conditions. Its expanding focus on plant-derived therapeutics is expected to contribute significantly to future market development.

Key Avenanthramides Companies:

·        Ceapro Inc.

·        Cosciens Biopharma Inc.

·        Chemicea Pharma

·        Symrise AG

·        Chen Lan gBio

·        Henan Steeda Industrial Co., Ltd.

·        BioCrick

Explore Grand View Horizon to see global and regional level statistics related to the Avenanthramides Market

Grand View Research offers

·         Focused market intelligence reports on specific geographies or high-growth segments.

·         Extended forecast timelines for long-term planning.

·         Competitor Benchmarking and Supply Chain Analysis

·         Inclusion of regulatory and policy assessments.

·         Inclusion of custom data models, KPIs, or applications unique to your business

·         Specific high-impact Data Decks and Tables to support effective decision making

·         And much more…

Looking for a report customized to your requirements? Explore our Custom Research Offering